Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid

Nobuyuki Takayama, Norihide Sato, Stephen G. O'Brien, Yasuo Ikeda, Shin Ichiro Okamoto

Research output: Contribution to journal › Article › peer-review

124 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid'. Together they form a unique fingerprint.

Medicine & Life Sciences